What is the recommended management for a patient with a Kyleena (levonorgestrel-releasing intrauterine system) in place for 7–8 years who is experiencing breakthrough bleeding?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Remove the Kyleena Immediately and Replace if Contraception is Desired

A Kyleena IUD that has been in place for 7-8 years is beyond its FDA-approved 5-year lifespan and must be removed, as it no longer provides reliable contraceptive protection and the breakthrough bleeding is likely related to device expiration. 1

Critical Issue: Device Has Exceeded Approved Duration

The FDA-approved duration for Kyleena is 5 years maximum 1. At 7-8 years:

  • Contraceptive efficacy is no longer guaranteed - the levonorgestrel reservoir is depleted
  • The device is functioning as an expired foreign body
  • Breakthrough bleeding at this timepoint signals hormonal depletion rather than a treatable side effect

Immediate Management Steps

1. Remove the Device Promptly

  • Schedule removal as soon as feasible
  • The patient has no contraceptive protection and should use backup contraception (condoms, spermicide) until removal and replacement 1
  • Rule out pregnancy before removal if sexually active

2. Evaluate for Underlying Pathology

Before attributing bleeding solely to the expired device, consider:

  • Pregnancy (ectopic or intrauterine)
  • Structural causes: polyps, fibroids, adenomyosis
  • Endometrial pathology: hyperplasia (especially given prolonged progestin exposure followed by declining levels)
  • STIs or cervicitis
  • Thyroid disorders or coagulopathy 2

Perform pelvic exam, pregnancy test, and consider transvaginal ultrasound if clinically indicated based on bleeding severity or other symptoms.

3. Counsel on Replacement Options

If the patient desires continued contraception:

  • Same-day replacement with new Kyleena or alternative LNG-IUS can be performed at removal visit
  • Discuss that a new device will cause initial irregular bleeding (first 3-6 months), but this is expected and different from the current situation 1
  • If she experienced amenorrhea with the previous device before it expired, she has a 40-50% chance of achieving amenorrhea again with a new device 3, 4

Why Standard Bleeding Management Does NOT Apply Here

The 2024 CDC guidelines for managing LNG-IUD breakthrough bleeding 2 note "No interventions identified" for LNG-IUD users experiencing bleeding irregularities. However, these recommendations apply to:

  • Devices within their approved lifespan
  • Early adaptation bleeding (first 6 months)
  • Ongoing but stable bleeding patterns

These guidelines do not address expired devices. Research on treatments like NSAIDs, tranexamic acid, or tamoxifen 5, 6 evaluated bleeding in the first 90 days after insertion or during active device use - not expired devices.

Common Pitfall to Avoid

Do not attempt to medically manage the bleeding while leaving an expired device in place. This approach:

  • Fails to address the root cause (depleted hormone reservoir)
  • Leaves the patient without contraceptive protection
  • Delays diagnosis of potential underlying pathology
  • May mask symptoms of serious conditions (endometrial hyperplasia, pregnancy)

Clinical Reasoning

An expired LNG-IUS transitions from a therapeutic device to a potential liability. The levonorgestrel release rate declines significantly after 5 years, eliminating both contraceptive efficacy and the endometrial suppression that prevents bleeding 3. The breakthrough bleeding represents return of normal menstrual patterns or potentially pathologic bleeding that was previously suppressed.

The only appropriate management is device removal with evaluation for pathology and discussion of replacement options 1.

References

Guideline

u.s. selected practice recommendations for contraceptive use, 2024.

MMWR Recommendations and Reports, 2024

Research

The levonorgestrel intrauterine system: the benefits of reduced bleeding.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 2001

Research

Consecutive Use of the 52 mg Levonorgestrel-releasing Intrauterine System: Variations in Bleeding Patterns.

Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.